Thursday, December 20, 2018 8:33:07 AM
Nidan,
Thanks again for the shout out. Here’s one thing we have both discussed before, the big picture view versus the details. I think we agree they are equally important but vastly different skill set, imo.
This is not passing the buck or a dodge, but I can truthfully say that falconer has a much better grasp on the fine details of the restoration of cellular homeostasis and he has painstakingly broken it all down for us in many insightful and readable but knowledgeable posts on several occasions.
I would defer to him in that area of expertise, either by reading some of his older posts, I think some are on the sticky compilation, or asking him to explain it anew.
I have a ton of respect for his knowledge...all of mine is borrowed from other sources which sometimes allow me to put things together but not take them apart, as others do so well.
I think both skills are necessary, valuable, and complimentary, but few folks, imo, possess both views in significant amounts.
Let me call upon falconer to share his knowledge/expertise in this field in answer to your question. If he is busy or otherwise unable, I’ll take my best stab, which will end up being links to the research of others in the field.
If you were to ask about the big picture strategy of how I think the trials will pan out - I got that one in the chamber. Short answer, we will should pass PDD easily, AD should also clear a comfortable margin and Rett appears promising but is the one I have some concerns over, to be truthful.
I’m confident that Anavex’s team has things figured out...I just don’t, at this point.
Also, I am willing to speculate on where Anavex would fit into the picture of a partnership or buyout and when, which I’ve posted before, but this field is in constant flux. I think we have reason to be optimistic about our prospects in this area as well - and I have faith in management that they are making all the right moves.
Best to you, Nidan...I think as another “big picture”, “survey the field depth” guy, you will understand my hesitations to narrow down to ground view and put everyone at a disadvantage.
Respect and regards always, bud.
Bio
Thanks again for the shout out. Here’s one thing we have both discussed before, the big picture view versus the details. I think we agree they are equally important but vastly different skill set, imo.
This is not passing the buck or a dodge, but I can truthfully say that falconer has a much better grasp on the fine details of the restoration of cellular homeostasis and he has painstakingly broken it all down for us in many insightful and readable but knowledgeable posts on several occasions.
I would defer to him in that area of expertise, either by reading some of his older posts, I think some are on the sticky compilation, or asking him to explain it anew.
I have a ton of respect for his knowledge...all of mine is borrowed from other sources which sometimes allow me to put things together but not take them apart, as others do so well.
I think both skills are necessary, valuable, and complimentary, but few folks, imo, possess both views in significant amounts.
Let me call upon falconer to share his knowledge/expertise in this field in answer to your question. If he is busy or otherwise unable, I’ll take my best stab, which will end up being links to the research of others in the field.
If you were to ask about the big picture strategy of how I think the trials will pan out - I got that one in the chamber. Short answer, we will should pass PDD easily, AD should also clear a comfortable margin and Rett appears promising but is the one I have some concerns over, to be truthful.
I’m confident that Anavex’s team has things figured out...I just don’t, at this point.
Also, I am willing to speculate on where Anavex would fit into the picture of a partnership or buyout and when, which I’ve posted before, but this field is in constant flux. I think we have reason to be optimistic about our prospects in this area as well - and I have faith in management that they are making all the right moves.
Best to you, Nidan...I think as another “big picture”, “survey the field depth” guy, you will understand my hesitations to narrow down to ground view and put everyone at a disadvantage.
Respect and regards always, bud.
Bio
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
